Advances in structural and molecular neuroimaging in Alzheimer's disease

Document Type

Journal Article

Publisher

Australasian Medical Publishing Company Pty. Ltd.

Faculty

Faculty of Computing, Health and Science

School

School of Medical Sciences / Centre of Excellence for Alzheimer's Disease Research and Care

RAS ID

12567

Comments

Ellis, K., Rowe, C., Szoeke, C., Villemagne, V., Ames, D., Chetelat, G., Martins, R. N., Masters, C., Fripp, J., Acosta, O., Raniga, P., Bourgeat, P., & Salvado, O. (2011). Advances in structural and molecular neuroimaging in Alzheimer's disease. Medical Journal of Australia, 194(4), S20-S23. Available here

Abstract

Longer life expectancies lead to increases in the prevalence of age-associated illnesses. The number of Australians with dementia is predicted to rise, from 234 000 in 2009 to over 1 million by 2050, as a result of the increased prevalence of Alzheimer’s disease (AD), the leading cause of dementia in the elderly. • Early diagnosis of AD will become more important as diseasemodifying therapies emerge within the next decade. • Advances in molecular neuroimaging with amyloid-β-specific radioligands for positron emission tomography, aided by magnetic resonance imaging techniques, allow detection of AD years before symptoms of dementia develop. • Longitudinal prospective studies, such as the Australian Imaging Biomarkers and Lifestyle (AIBL) study of ageing, will determine the sensitivity and specificity of these analysis techniques for diagnosing AD and predicting cognitive MJA 2011; 194: S20–S23 decline.

Access Rights

subscription content

Link to Full Text

Share

 
COinS